Bold Therapeutics Inc.

Bold Therapeutics Inc. company information, Employees & Contact Information

Explore related pages

Bold Therapeutics Inc. email format Bold Therapeutics Inc. management contacts

Related company profiles:

Bold Therapeutics is the world leader in the development of novel metallotherapeutics. Bold Therapeutics' lead program, BOLD-100, has demonstrated positive safety and efficacy in Phase 2 clinical trials in colorectal, biliary tract and gastric cancers, with presentations at ASCO 2024 and ASCO GI 2024. Bold Therapeutics expects to initiate pivotal Phase 3 trials in the near future.

Company Details

Employees
20
Founded
-
Address
850 W Hastings St, Suite 515,canada
Phone
+1 (604) 262-9899
Email
in****@****ics.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Website
bold-therapeutics.com
HQ
Vancouver, British Columbia
Competitors
Xenon Pharmaceuticals Inc., Intezyne Technologies, Virogin Biotech, Qu Biologics Inc., Acuitas Therapeutics, AbCellera, Gandeeva Therapeutics, Symvivo Corporation, Aspect Biosystems, VoxCell BioInnovation.
Looking for a particular Bold Therapeutics Inc. employee's phone or email?

Bold Therapeutics Inc. Questions

News

Bold Therapeutics Announces Presentation of Late-Breaking Data on BOLD-100's Unique Ability to Mitigate Oxaliplatin-Induced Peripheral Neuropathy (OIPN) - PR Newswire

Bold Therapeutics Announces Presentation of Late-Breaking Data on BOLD-100's Unique Ability to Mitigate Oxaliplatin-Induced Peripheral Neuropathy (OIPN) PR Newswire

Bold Therapeutics Presents Late-Breaking Poster on BOLD-100's Unique Ability to Mitigate Oxaliplatin-Induced Peripheral Neuropathy (OIPN) at AACR Annual Meeting 2025 - PR Newswire

Bold Therapeutics Presents Late-Breaking Poster on BOLD-100's Unique Ability to Mitigate Oxaliplatin-Induced Peripheral Neuropathy (OIPN) at AACR Annual Meeting 2025 PR Newswire

Metastatic Colorectal Cancer Clinical Trial Pipeline Accelerates as 150+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - GlobeNewswire

Metastatic Colorectal Cancer Clinical Trial Pipeline Accelerates as 150+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight GlobeNewswire

Jasper Therapeutics Executives Make Bold Moves with Major Stock Purchases! - TipRanks

Jasper Therapeutics Executives Make Bold Moves with Major Stock Purchases! TipRanks

Metastatic Colorectal Cancer Pipeline Outlook 2025: Insights Into Therapies, Research, and Market Potential - The Globe and Mail

Metastatic Colorectal Cancer Pipeline Outlook 2025: Insights Into Therapies, Research, and Market Potential The Globe and Mail

FDA Grants Orphan Drug Status to BOLD-100 For the Treatment of Gastric Cancer - Targeted Oncology

FDA Grants Orphan Drug Status to BOLD-100 For the Treatment of Gastric Cancer Targeted Oncology

FDA Grants Orphan Drug Designation to BOLD-100 for Gastric Cancer - OncLive

FDA Grants Orphan Drug Designation to BOLD-100 for Gastric Cancer OncLive

'My Time at Moffitt Was Instrumental' - Moffitt

'My Time at Moffitt Was Instrumental' Moffitt

Bold Therapeutics to begin Phase Ib/IIa trial of GI cancer therapy in US - Clinical Trials Arena

Bold Therapeutics to begin Phase Ib/IIa trial of GI cancer therapy in US Clinical Trials Arena

Bold Therapeutics Announces Positive Phase 2 Safety and Efficacy Results for BOLD-100 in Advanced Metastatic Biliary Tract and Gastric Cancers at ASCO 2024 - PR Newswire

Bold Therapeutics Announces Positive Phase 2 Safety and Efficacy Results for BOLD-100 in Advanced Metastatic Biliary Tract and Gastric Cancers at ASCO 2024 PR Newswire

10 Promising Therapies for Hard-to-Treat Cancers - BioSpace

10 Promising Therapies for Hard-to-Treat Cancers BioSpace

Insights into Mechanisms and Promising Triple Negative Breast Cancer Therapeutic Potential for a Water-Soluble Ruthenium Compound - ACS Publications

Insights into Mechanisms and Promising Triple Negative Breast Cancer Therapeutic Potential for a Water-Soluble Ruthenium Compound ACS Publications

Boundless Bio’s ‘BOLD’ IPO Reels In $100M for a New Kind of Cancer Drug - MedCity News

Boundless Bio’s ‘BOLD’ IPO Reels In $100M for a New Kind of Cancer Drug MedCity News

Pancreatic Cancer Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Biotherapeutics, Keymed Biosciences Co. Ltd - Barchart.com

Pancreatic Cancer Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Biotherapeutics, Keymed Biosciences Co. Ltd Barchart.com

Jeff Marrazzo's Big, Bold Cell and Gene Therapy Vision - Philadelphia Magazine

Jeff Marrazzo's Big, Bold Cell and Gene Therapy Vision Philadelphia Magazine

Bold Therapeutics Selected as a 2023 'Company to Watch' by Life Sciences British Columbia - PR Newswire

Bold Therapeutics Selected as a 2023 'Company to Watch' by Life Sciences British Columbia PR Newswire

Colorectal Cancer Clinical Trials Pipeline Analysis Featuring 125+ Key Companies by DelveInsight - GlobeNewswire

Colorectal Cancer Clinical Trials Pipeline Analysis Featuring 125+ Key Companies by DelveInsight GlobeNewswire

Coeptis Therapeutics Makes Bold Strides in Innovation with the Acquisition of NexGenAI Affiliates Network Platform and Launch of Coeptis Technologies - PR Newswire

Coeptis Therapeutics Makes Bold Strides in Innovation with the Acquisition of NexGenAI Affiliates Network Platform and Launch of Coeptis Technologies PR Newswire

Gallant Therapeutics Raises Over $15 Million in Series A - GlobeNewswire

Gallant Therapeutics Raises Over $15 Million in Series A GlobeNewswire

Bold Therapeutics Successfully Completes Phase 1b Trial and Advances into Global Phase 2 Trial of BOLD-100 in the Treatment of Advanced GI Cancers - PR Newswire

Bold Therapeutics Successfully Completes Phase 1b Trial and Advances into Global Phase 2 Trial of BOLD-100 in the Treatment of Advanced GI Cancers PR Newswire

Meet Bold Health: Digital Therapeutics Startup Helping People Improve Digestive Health - Forbes

Meet Bold Health: Digital Therapeutics Startup Helping People Improve Digestive Health Forbes

BOLD Stock Price and Chart — NASDAQ:BOLD - TradingView

BOLD Stock Price and Chart — NASDAQ:BOLD TradingView

Companies like Bold Therapeutics Inc.

Xenon Pharmaceuticals Inc. logo - Similar company to Bold Therapeutics Inc.

Xenon Pharmaceutical...

371
Virogin Biotech logo - Similar company to Bold Therapeutics Inc.

Virogin Biotech

32
AbCellera logo - Similar company to Bold Therapeutics Inc.

Abcellera

617
Intezyne Technologies logo - Similar company to Bold Therapeutics Inc.

Intezyne Technologies

NA
Gandeeva Therapeutics logo - Similar company to Bold Therapeutics Inc.

Gandeeva Therapeutics

28
Qu Biologics Inc. logo - Similar company to Bold Therapeutics Inc.

Qu Biologics Inc.

18
Acuitas Therapeutics logo - Similar company to Bold Therapeutics Inc.

Acuitas Therapeutics

77
Aspect Biosystems logo - Similar company to Bold Therapeutics Inc.

Aspect Biosystems

119
VoxCell BioInnovation logo - Similar company to Bold Therapeutics Inc.

Voxcell Bioinnovation

33
Symvivo Corporation logo - Similar company to Bold Therapeutics Inc.

Symvivo Corporation

2

Top Bold Therapeutics Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant